GLP1R in Parkinson's Disease

Sponsor
Oslo University Hospital
Study ID
NCT03659682
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    subcutaneous, 1.0 mg, weekly, 48 months

Study Details

The purpose of the study is to test the neuroprotective and anti-inflammatory properties of semaglutide in idiopathic Parkinson's disease (PD)

Key Dates

Start date
Jan 2, 2019
Status verified
Sep 2018
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: semaglutide
    Ozempic- 1.0 mg administered subcutaneously once weekly
  • Placebo Comparator: placebo
    Placebo, 1.0 mg administered subcutaneously once weekly

Primary Outcome Measure

Motor Function [ Time Frame: 48 months ]

Central Contacts

Related Studies